Why COPD Research Is So Important

COPD affects the lungs and refers to a group of diseases including both Emphysema and Chronic Bronchitis. COPD results in symptoms that can include frequent coughing, trouble breathing, chest tightness, wheezing and fatigue.

COPD is usually the result of being a smoker or having a history of smoking, however, others at higher risk include workers who have had prolonged exposure to things like harsh chemical fumes or air-borne particles, for example.

Medications for COPD exist, but many of those with moderate-to-severe disease take more than one to control symptoms. So, some may find it hard to take them correctly, while others may feel that they aren’t working well enough. Still others may prefer taking a pill or getting a periodic shot over using inhalers.

Take the next step to see if you qualify for local research studies for people with COPD, which stands for Chronic Obstructive Pulmonary Disease. But don’t delay — space is limited!

Get started now

How does it work?

1

Tell us a little bit about yourself

2

Answer some questions about your health

3

We will connect you to available studies in your area

Just takes a few minutes

Get started now

COVID-19 update — we remain open.

For the safety of both staff and patients, we require that our research sites are COVID-19 SMART facilities. That means they use best practices to reduce virus exposure and are dedicated to ensuring they remain open and available for the research of investigational medications.

COVID-19 SMART steps we are taking to ensure safety include:

  • Greatly increased availability of video office visits
  • Ensuring social distancing measures are taken in all waiting areas
  • Continuing the practice of cleaning and disinfecting exam rooms thoroughly between every visit
  • Appropriate personal protective equipment (PPE) for all staff members at our health clinics

AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.